Jefferies Raises Price Target on Bristol Myers Squibb (BMY)

Jefferies Raises Price Target on Bristol Myers Squibb (BMY)


Analysts at Jefferies & Co. boosted the price target on pharmaceutical company Bristol Myers Squibb Co. (BMY) on Tuesday, stating that 2013 will be a pivotal year for shaping long-term growth.

The analysts maintain a “Buy” rating on BMY and see shares reaching $41. This new target suggests an 11% upside to Monday’s closing price of $36.93.

Bristol Myers shares were down slightly during morning trading on Tuesday. The stock is up about +15% over the past year.

The Bottom Line
Shares of Bristol Myers (BMY) have a dividend yield of 3.79% based on last night’s closing price of $36.93 and the company’s annualized dividend payout of $1.40 per share.

Bristol Myers Squibb Co. (BMY) is recommended at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today